The hottest research team developed a new biosenso

2022-08-08
  • Detail

The research team developed a new biosensor that can separate and target leukemic stem cells

all stem cells can reproduce, proliferate and differentiate. Because of these characteristics, leukemic stem cells are the most malignant of all leukemic cells. Understanding the regulation mode of leukemic stem cells has become an important field for cancer research with a demand of 200000 m2

a research team at Tel Aviv University has now designed a new biosensor that can separate and target leukemic stem cells. The research team, led by Dr. Michael milyavsky of the Department of pathology of tau sakler Medical College, discussed their unique genetic coding sensor and their ability to identify, isolate and identify leukemic stem cells in their study on leukemia published on January 31

"the main reason for the low survival rate of blood cancer is the inherent resistance of leukemia stem cells to treatment," Dr. milyavsky said. "However, only a small number of leukemia cells have high regeneration potential, and it is this regeneration that leads to disease recurrence. The lack of tools for specific isolation of leukemia stem cells has ruled out the comprehensive research and specific targeting of these stem cells so far."

until recently, cancer researchers used markers on the cell surface to distinguish leukemia stem cells from most cancer cells, but the effect is limited. "There are hidden cancer stem cells that, despite their stem cell function, can still express differentiated surface markers. This allows these cells to escape targeted therapy," Dr. milyavsky explained. "By labeling leukemic cells only according to their stem cell characteristics, our sensor tries to overcome the problem of surface labeling based on three material development paths of mixed materials.

" we believe that our biosensor can provide a prototype for accurate oncology work to target patient specific leukemic stem cells to fight this deadly disease. "

scientists searched the genome database for "enhancers", which are genome-specific regulatory regions that are particularly active in stem cells. Then, they used genome engineering to develop a sensor, which is composed of stem cell active enhancers fused with fluorescent genes, and fluorescent genes label cells with active enhancers

scientists can also prove that the leukemia stem cells with positive sensors are sensitive to the known and inexpensive 4-HPR (fenvidamine) anticancer drugs, which provides a new biomarker for patients who may benefit from the drugs that are initially considered to be insured by insurance companies, insured by material manufacturers, and benefited by material users

"using this sensor, we can screen personalized drugs for drugs by coding the bar code of the patient's own leukemia cells, so as to find the best drug combination that can target leukemia and leukemia stem cells in the body at the same time," Dr. miliavski concluded. "We are also interested in developing killer genes that can eradicate specific leukemic stem cells where our sensors are active."

researchers are studying those genes that are active in leukemia stem cells, hoping to find medicinal targets

Copyright © 2011 JIN SHI